Ultrasound Guided TAPB vs Surgical TAPB With Bupivacaine in Cesarean Section

Sponsor
Al-Azhar University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05750992
Collaborator
(none)
50
1
2
2.7
18.8

Study Details

Study Description

Brief Summary

The aim of this study is to compare Surgical Transversus abdominis plane block and Ultrasound guided transversus abdominis plane block (TAPB) as a postoperative analgesic regimen in female patients undergoing elective cesarean delivery.

Condition or Disease Intervention/Treatment Phase
  • Procedure: surgical TAP block
  • Procedure: US guided TAP block
N/A

Detailed Description

Caesarean delivery rates have been increasing worldwide nowadays. At rate of [52%], Egypt stands out among countries with the world's highest cesarean delivery percentages . Within the Arab region, rate of cesarean section far higher in Egypt than other Arab countries.

A much simpler and theoretically superior means of establishing a TAP block. When using a transcutaneous (conventional) approach there is always the risk of peritoneal puncture with its attendant complications. Moreover, there are technical difficulties, especially in obese women and the procedure requires specialist equipment, a skilled operator and training in ultrasonography. Our approach obviates these risks and difficulties because the procedure is carried out under direct vision, and it is much easier to perform by the surgeon during caesarean section.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Ultrasound Guided Transversus Abdominis Plane Block (TAPB) vs Surgical TAPB With Bupivacaine for Acute Pain Control in Cesarean Section: A Randomized Clinical Trial
Anticipated Study Start Date :
Mar 10, 2023
Anticipated Primary Completion Date :
May 30, 2023
Anticipated Study Completion Date :
May 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: surgical TAP block

twenty-five pregnant women will receive surgical TAP block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.

Procedure: surgical TAP block
performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
Other Names:
  • bupivacaine, normal saline, fentanyl, pethidine
  • Active Comparator: US guided TAP block

    25 pregnant women will receive US guided T.A.P block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.

    Procedure: US guided TAP block
    performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
    Other Names:
  • bupivacaine, normal saline, fentanyl , pethidine
  • Outcome Measures

    Primary Outcome Measures

    1. Time to perform block. [1 hour postoperatively]

      The time taken to perform the block will be recorded by an independent observer.

    Secondary Outcome Measures

    1. Heart rate [24 hours postoperatively]

      Patients hemodynamics (heart rate will be recorded)

    2. Mean arterial blood pressure [24 hours postoperatively]

      Patients hemodynamics (mean arterial blood pressure will be recorded)

    3. Pain score [24 hours postoperatively]

      The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    4. Time to first analgesic request [24 hours postoperatively]

      The time to first analgesic request will be recorded

    5. Amount of post operative analgesic consumption [24 hours postoperatively]

      The amount of post operative analgesic consumption will be recorded

    6. Time spent in operating room [24 hours postoperatively]

      The time spent in operating room will be recorded

    7. Incidence of Adverse reactions [24 hours postoperatively]

      Adverse events will be recorded such as nausea, vomiting, hypotension (Mean arterial blood pressure < 20% of baseline readings and will be managed by ephedrine 5 mg IV and/or normal saline IV) and bradycardia (heart rate < 60 beats/min and will be managed by atropine 0.6 mg IV).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 35 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Full term pregnant women

    • Older than 21 years of age

    • Had elective cesarean section with Pfannenstiel incision.

    Exclusion Criteria:
    • Patients with cesarean section using different surgical incision

    • History of addiction [including opioids and benzodiazepines]

    • Allergy to the anesthetic analgesia

    • Psychological disorders

    • Coagulopathies

    • Infection at the block injection site.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kohaf Cairo Egypt 11865

    Sponsors and Collaborators

    • Al-Azhar University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Neveen Abd El Maksoad Kohaf, Lecturer of Clinical Pharmacy, Al-Azhar University
    ClinicalTrials.gov Identifier:
    NCT05750992
    Other Study ID Numbers:
    • DFM-IRB 00012367- 23-02-006
    First Posted:
    Mar 2, 2023
    Last Update Posted:
    Mar 2, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 2, 2023